• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Immunotoxin complementation of HAART to deplete persisting HIV-infected cell reservoirs.

作者信息

Berger Edward A, Pastan Ira

机构信息

Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.

出版信息

PLoS Pathog. 2010 Jun 10;6(6):e1000803. doi: 10.1371/journal.ppat.1000803.

DOI:10.1371/journal.ppat.1000803
PMID:20548940
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2883583/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2770/2883583/509d592b43eb/ppat.1000803.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2770/2883583/b59986934c00/ppat.1000803.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2770/2883583/509d592b43eb/ppat.1000803.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2770/2883583/b59986934c00/ppat.1000803.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2770/2883583/509d592b43eb/ppat.1000803.g002.jpg

相似文献

1
Immunotoxin complementation of HAART to deplete persisting HIV-infected cell reservoirs.高效抗逆转录病毒治疗（HAART）的免疫毒素互补作用以清除持续存在的HIV感染细胞储存库。
PLoS Pathog. 2010 Jun 10;6(6):e1000803. doi: 10.1371/journal.ppat.1000803.
2
Persistence of genital tract T cell responses in HIV-infected women on highly active antiretroviral therapy.高效抗逆转录病毒治疗后，HIV 感染女性生殖道 T 细胞反应的持续存在。
J Virol. 2010 Oct;84(20):10765-72. doi: 10.1128/JVI.00518-10. Epub 2010 Aug 4.
3
An anti-CD45RO immunotoxin kills HIV-latently infected cells from individuals on HAART with little effect on CD8 memory.一种抗CD45RO免疫毒素可杀死接受高效抗逆转录病毒治疗（HAART）的个体中潜伏感染HIV的细胞，而对CD8记忆细胞影响很小。
Proc Natl Acad Sci U S A. 2004 Feb 24;101(8):2494-9. doi: 10.1073/pnas.0308381100.
4
CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Swiss HIV Cohort Study.
Lancet. 1998 Mar 7;351(9104):723-4. doi: 10.1016/s0140-6736(98)24010-4.
5
Low-level viremia and proviral DNA impede immune reconstitution in HIV-1-infected patients receiving highly active antiretroviral therapy.低水平病毒血症和前病毒DNA阻碍接受高效抗逆转录病毒治疗的HIV-1感染患者的免疫重建。
J Infect Dis. 2005 Feb 1;191(3):348-57. doi: 10.1086/427340. Epub 2004 Dec 30.
6
Association between cellular human immunodeficiency virus DNA level and immunological parameters in patients with undetectable plasma viremia level during highly active antiretroviral therapy.高效抗逆转录病毒治疗期间血浆病毒血症水平检测不到的患者，其细胞内人类免疫缺陷病毒DNA水平与免疫参数之间的关联
J Clin Microbiol. 2005 Dec;43(12):6183-5. doi: 10.1128/JCM.43.12.6183-6185.2005.
7
Seroreversion of HIV antibodies in patients with prolonged suppression of viraemia under HAART.在高效抗逆转录病毒治疗（HAART）下病毒血症长期受到抑制的患者中，HIV抗体血清学逆转。
AIDS. 2006 Jun 26;20(10):1460-2. doi: 10.1097/01.aids.0000233584.10209.43.
8
Clonal evolution of CD8+ T-cell expansions in HIV-infected patients on long-term HAART.长期接受高效抗逆转录病毒治疗的HIV感染患者中CD8 + T细胞扩增的克隆进化
Clin Exp Immunol. 2001 Nov;126(2):280-6. doi: 10.1046/j.1365-2249.2001.01665.x.
9
MHC class II genotype and the control of viremia in HIV-1-infected individuals on highly active antiretroviral therapy.MHC II类基因型与接受高效抗逆转录病毒治疗的HIV-1感染个体的病毒血症控制
J Clin Invest. 2001 Mar;107(5):549-51. doi: 10.1172/JCI12430.
10
Significant link between sCD30 changes and HIV viremia in patients treated with HAART.接受高效抗逆转录病毒治疗（HAART）的患者中，可溶性CD30（sCD30）变化与HIV病毒血症之间存在显著关联。
J Med Virol. 2006 Dec;78(12):1513-9. doi: 10.1002/jmv.20733.

引用本文的文献

1
Conjugation of anti-HIV gp41 monoclonal antibody to a drug capable of targeting resting lymphocytes produces an effective cytotoxic anti-HIV immunoconjugate.将抗 HIV gp41 单克隆抗体与能够靶向静止淋巴细胞的药物结合，可产生有效的细胞毒性抗 HIV 免疫缀合物。
J Virol. 2024 Oct 22;98(10):e0064724. doi: 10.1128/jvi.00647-24. Epub 2024 Sep 16.
2
Identification of Anti-gp41 Monoclonal Antibodies That Effectively Target Cytotoxic Immunoconjugates to Cells Infected with Human Immunodeficiency Virus, Type 1.鉴定能有效将细胞毒性免疫偶联物靶向到1型人类免疫缺陷病毒感染细胞的抗gp41单克隆抗体。
Vaccines (Basel). 2023 Apr 12;11(4):829. doi: 10.3390/vaccines11040829.
3

本文引用的文献

1
The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic.抗逆转录病毒疗法的发展及其对 HIV-1/AIDS 大流行的影响。
Antiviral Res. 2010 Jan;85(1):1-18. doi: 10.1016/j.antiviral.2009.10.002. Epub 2009 Dec 16.
2
Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target.一位非洲捐赠者体内广泛且强效的中和抗体揭示了一个新的HIV-1疫苗靶点。
Science. 2009 Oct 9;326(5950):285-9. doi: 10.1126/science.1178746. Epub 2009 Sep 3.
3
A simian immunodeficiency virus-infected macaque model to study viral reservoirs that persist during highly active antiretroviral therapy.
Targeting the Inside of Cells with Biologicals: Toxin Routes in a Therapeutic Context.
靶向细胞内的生物制品：治疗环境中的毒素途径。
BioDrugs. 2023 Mar;37(2):181-203. doi: 10.1007/s40259-023-00580-y. Epub 2023 Feb 2.
4
Antibody Conjugates for Targeted Therapy Against HIV-1 as an Emerging Tool for HIV-1 Cure.用于抗HIV-1靶向治疗的抗体偶联物作为HIV-1治愈的新兴工具
Front Immunol. 2021 Jul 1;12:708806. doi: 10.3389/fimmu.2021.708806. eCollection 2021.
5
Antiviral Activity of Ribosome-Inactivating Proteins.核糖体失活蛋白的抗病毒活性
Toxins (Basel). 2021 Jan 22;13(2):80. doi: 10.3390/toxins13020080.
6
An immunotoxin targeting Ebola virus glycoprotein inhibits Ebola virus production from infected cells.一种针对埃博拉病毒糖蛋白的免疫毒素可抑制感染细胞中埃博拉病毒的产生。
PLoS One. 2021 Jan 7;16(1):e0245024. doi: 10.1371/journal.pone.0245024. eCollection 2021.
7
Immunogenicity of Immunotoxins Containing Exotoxin A: Causes, Consequences, and Mitigation.免疫毒素中包含的外毒素 A 的免疫原性：原因、后果和缓解。
Front Immunol. 2020 Jun 26;11:1261. doi: 10.3389/fimmu.2020.01261. eCollection 2020.
8
Principles of Immunotherapy: Implications for Treatment Strategies in Cancer and Infectious Diseases.免疫治疗原理：对癌症和传染病治疗策略的影响
Front Microbiol. 2018 Dec 21;9:3158. doi: 10.3389/fmicb.2018.03158. eCollection 2018.
9
Antiviral Immunotoxin Against -1: Targeted Inhibition of Viral Replication and Apoptosis of Infected Cell.抗-1抗病毒免疫毒素：对病毒复制的靶向抑制及感染细胞的凋亡
Front Microbiol. 2018 Apr 4;9:653. doi: 10.3389/fmicb.2018.00653. eCollection 2018.
10
The B-Cell Follicle in HIV Infection: Barrier to a Cure.HIV 感染中的 B 细胞滤泡：治愈的障碍。
Front Immunol. 2018 Jan 25;9:20. doi: 10.3389/fimmu.2018.00020. eCollection 2018.
一种用于研究在高效抗逆转录病毒疗法期间持续存在的病毒储存库的猿猴免疫缺陷病毒感染猕猴模型。
J Virol. 2009 Sep;83(18):9247-57. doi: 10.1128/JVI.00840-09. Epub 2009 Jul 1.
4
Analysis of human immunodeficiency virus type 1 viremia and provirus in resting CD4+ T cells reveals a novel source of residual viremia in patients on antiretroviral therapy.对1型人类免疫缺陷病毒血症和静息CD4+ T细胞中前病毒的分析揭示了接受抗逆转录病毒治疗患者残余病毒血症的新来源。
J Virol. 2009 Sep;83(17):8470-81. doi: 10.1128/JVI.02568-08. Epub 2009 Jun 17.
5
A step ahead on the HIV collaboratory.
Science. 2009 Jun 5;324(5932):1264-5. doi: 10.1126/science.324_1264b.
6
HIV interactions with monocytes and dendritic cells: viral latency and reservoirs.人类免疫缺陷病毒与单核细胞和树突状细胞的相互作用：病毒潜伏期与病毒储存库
Retrovirology. 2009 Jun 1;6:51. doi: 10.1186/1742-4690-6-51.
7
Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy.对于接受高效抗逆转录病毒治疗的患者，强化治疗并不能降低残留的HIV-1病毒血症。
Proc Natl Acad Sci U S A. 2009 Jun 9;106(23):9403-8. doi: 10.1073/pnas.0903107106. Epub 2009 May 22.
8
HIV latency: present knowledge, future directions.HIV潜伏：现有知识与未来方向。
Future Virol. 2006;1(6):733-745. doi: 10.2217/17460794.1.6.733.
9
Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia.重组免疫毒素RFB4(dsFv)-PE38（BL22）治疗毛细胞白血病患者的II期试验
J Clin Oncol. 2009 Jun 20;27(18):2983-90. doi: 10.1200/JCO.2008.20.2630. Epub 2009 May 4.
10
The challenge of finding a cure for HIV infection.寻找治愈艾滋病毒感染方法的挑战。
Science. 2009 Mar 6;323(5919):1304-7. doi: 10.1126/science.1165706.